Revista espanola de enfermedades digestivas
Cure8 research brief
Why This Matters
Patients with moderate-to-severe Crohn's disease who do not respond to anti-TNF drugs have limited options. This study suggests combining ustekinumab with upadacitinib may improve endoscopic healing versus either drug alone at 12–24 weeks.
Who Should Pay Attention
Adults with moderate-to-severe Crohn's disease after anti-TNF failure; clinicians treating refractory IBD; researchers of combination biologic/small-molecule therapies.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study compared three groups: UST+UPA (30 mg), UST alone, and UPA (45 mg) alone in 110 patients. The combination arm had substantially higher endoscopic remission (51.2%) versus UST (17.5%) or UPA (24.1%).
Clinical remission was also higher in the combination group versus UST, while adverse events were more frequent with combination therapy but without reported serious events. The report is a multicenter retrospective study (not a randomized controlled trial).
That affects how confidently we can interpret comparative effectiveness and safety; selection bias and unmeasured confounding can influence results. Decisions about combination advanced therapy should be made with a treating clinician.
Keep In Mind
Retrospective design, short follow-up (12–24 weeks), and possible selection bias limit causal conclusions. The source is an abstract-level journal article; confirmatory randomized controlled trials and longer safety data are needed.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationRevista espanola de enfermedades digestivas
AuthorsChangqin Liu, Qi Geng, Lu Lu +7 more
InstitutionGastroenterology, Shanghai Tenth People's Hospital, Tongji University, China.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedSep 9, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
Switching Between Anti-TNFs and Other Biologic Drugs in Paediatric Inflammatory Bowel Disease: A Narrative Review and Practical Clinical Guide.
Switching biologics is a frequent and consequential decision in children with IBD; using TDM and a mechanism‑based approach can help choose whether to optimize, switch within class, or change drug class.
Immunomodulators and advanced therapies for maintenance of remission in Crohn's disease: systematic review and network meta-analysis.
A broad comparison of many maintenance therapies helps patients and clinicians understand which drugs have trial evidence for preventing relapse or loss of response in Crohn's disease. The review highlights adalimumab,...